现代中药 人类共享

中药产业是我国医药产业独有的特色和优势领域,也是典型的民族工业之一,中医药文化同时又是上下五千年璀璨的中华文化的重要组成部分。中药产业植根于我国独具的自然、人文及市场资源,在全球化的产业竞争环境中具有显著的比较优势。由于国际知识产权保护的挑战和我国进入WTO后面临的国际大医药集团对我国市场的强烈竞争压力,中药产业在我国医药产业的战略地位愈显重要。

In accordancc with the idea of socking thethcory that man is an integral part of nature andheightening tne quality of life and relying on itsextension achievements of scienlific research, TaslyGroup fixes ite position on the Great Health Indus-try and devolops industrics of pianting, healthcareproducts, cosmetics, healthy drinks and new-styiepackaging. Tasly pcople have ostablished the trans-contary development scrategy of creating the firstbrand of traditional Chinese inedicincs and the ra-tional high-tech pharmaceutical onterprisol. Sinceits cstablishment seven years ago. Tasly Group hasbeen developing rapidly on the road of industrial-ization of high-technology. with high-technologyas its core marketplace its guide, marketing itsmotivity and quality its guarantee. Its sales revenueas well as the profit and tax are increasing at therate of 94% averagely per year. Ite assots haveincreased by 125 limes, and its accumulative total ofthe profit and tax reaches l billion yuan. Duringthe seven years, Tasly Group has created six thefirst's of the pharmaceutical industry in China,riz. the first drug. that is, Compound DanshenDripping Pill, of modern Traditional Chinese Medi-cines whose Investigational New Drug applicationsare approved by the FDA in the USA; the firstgiant granite embossment, the Chinese NationalMeducine Drawing, describing the history of thetraditional Chinese medicine; the first domonstra-tion enterprise of modern TCM industrial development;the first enterprise the designed and undertook theTraditional Chinese Medicine Cultural Festivalsuccessfully; the first Danshen plantation in linewith GAP; the first pharmaceutical enterprise thatwins the first prize of the national Enterprise Man-agement Modemization Innovation Achievement. Tasly Group has established the modern TCMplantations according to tho world-recognized GAPstandard. And it invested RMB 450 million to es-tablish the Tasly High-Tech Garden in line withthe international Good Manufacture Practice (GMP),and obtained the certificate of national GMP andISO9001 2000. The garden is the biggest drippingpill manufacturing base and one of the high-techrepresentative projects of the State Committee ofPlanning and Development. When the project isfinished entirely. the annual production value isexpected to be more than RMB 10 billion. TaslyGroup first proposed the Good Extraction Practice(GEP) and established the GEP criteria. Tasty Grouphas 1 billion to establish the Tasly Botani-cal R&D Institute, the Tasly Institute of BiologicalProducts and the Tasly Institute of Chemical Medi-cines in recent years, which form a world-first-ciass R&D system. Tasly has a series of health and life threateningdiscases-oriented structure of products, and mul-tiple ones such as granule, capsule, soft capsule,tablet. injection, modified reiease preparations etc.The company is taking the Chinese herbal medi-cines for corebral and cardiovascular discases as itsmain task of development, making every effort todevelop three to five high quality herbal medicines,which will be classified on the basis of syndromesaccording to TCM theory, and improving indi-vidualized regime for TCM treatment Research anddevelopment of Cardiotonic pills as weil as its ana-iogs have been listed into many a few programssponsored by Chinese govemment, such as the MostImportant of 'Industrialization Plan for Mod-ernization in the Traditional Chinese Medicine',Important Science and Technology AchievementExpending Program in the Ninth Five-Year Plan,and the ‘973’Project for Basic Scientific Researchgranted by Ministry of Science And Technology;And the Pilot Engineering Project for Hi-Tech In-dustrialization and Special Key Project Plan for TCMModernization sponsored by the State Commissionof Planning. At present, the new--generation computer-con-trolled automatic product line of dripping pill prepa-ration is the biggest one of its sort in China, withthe yearly production value reaching 2 billion Yuar.Two product lines of novel medicaments, introducedfrom IMA, Italy, have been put into operation.Other introduce